150 Orchard Road
Orchard Plaza 08-02
214 articles with VolitionRX
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
The resulting blood-based test will be used for triaging individuals testing positive in Low Dose CT lung cancer screening.
Conference call to discuss financial and operational results scheduled for Wednesday, November 13 at 8:30 a.m. U.S. Eastern Time
VolitionRx Limited announced the confirmation of a further $500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its subsidiary Volition Veterinary Diagnostics Development, LLC.
Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
VolitionRx Limited announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department will be presenting at the Veterinary Cancer Society Annual Conference in Houston taking place this weekend.
This breakthrough could be used in two ways, firstly to increase specificity in Volition's current assays by removing the background signal and secondly, as an enabling technology in sequencing-based liquid biopsies by enriching nucleosomes of cancer origin from the blood.
Conference call to take place Tuesday, August 13, 2019 at 8:30 am Eastern time
VolitionRx Limited announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase $4.8 million in aggregate amount of shares of our common stock.
VolitionRx Limited has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. to help introduce the Nu.Q platform to China.
To date, Agencies from the Region have awarded Volition an aggregate of approximately $6 million in non-dilutive funding including this most recent award.
VolitionRx Limited announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University.
Conference call to take place Thursday, May 9, 2019 at 8:30 am Eastern time
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
VolitionRx Limited hosted a Capital Markets Day at the New York Stock Exchange to update interested parties on its recent progress.
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.
VolitionRx Limited announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University.
VolitionRx Limited announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019.
Conference call to discuss financial and operational results scheduled for Thursday, March 14 at 8:30 a.m. U.S. Eastern Time
VolitionRx Limited announced it will host a conference call on Thursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2018.
VolitionRx Limited today announced financial results and a business update for the quarter ended September 30, 2018.
Announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer.
VolitionRx Limited announced financial results and a business update for the quarter ended June 30, 2018.